Mode
Text Size
Log in / Sign up
N/A Completed N=13 Prevention

Efficacy of a Multimodal Brain Health Intervention for Older African Americans

Cognitive Impairment, Mild · Cognitive Decline
Source: ClinicalTrials.gov NCT04863378 ↗
Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Jan 2025
Primary outcomePrimary: Daily Average Steps Recorded by Actigraphy Watch — 2570; 1140 daily step count

Summary

This study tests the feasibility, acceptability, and efficacy of a multimodal intervention (walking, social engagement, and reminiscence), including the use of wearable digital biomarkers, for cognitively healthy and mildly cognitively impaired African Americans aged 65 and older.

Outcome Measures

OutcomeResultp-value
PRIMARY
Daily Average Steps Recorded by Actigraphy Watch
2570; 1140
PRIMARY
Daily Average Sleep Time Recorded by an Emfit QS Sleep Sensor
6.71; 5.07
PRIMARY
Weekly Health Update Survey Response Time
195; 472
PRIMARY
Pittsburgh Sleep Quality Index
7.00; 5.60
PRIMARY
Weekly Survey Completion Rate
91; 60

Eligibility Criteria

Inclusion Criteria for walkers:

  • Self-identified African American,
  • Age > 65 years old
  • Reside or resided for >10 years in Portland's historically Black neighborhoods (to be familiar with Memory Markers about this area),
  • Able to ambulate independently.
  • Meeting Cognition Criteria
  • Participants with MCI (Mild Cognitive Impairment) will meet criteria consistent with the criteria outlined by the NIA-Alzheimer's Association workgroup
  • Participants without cognitive impairment will have a Montreal Cognitive Assessment (MoCA) score > 24 (and not meet MCI criteria). Participants' cognitive function should allow them to get to and from walk locations independently or with minimal assistance.
  • Cognitive function allows independent (or minimally assisted) travel to and from walk locations
  • In-home reliable broadband internet (for weekly online surveys).
  • Ability to read, speak, and understand English

Exclusion Criteria

  • Self-reported or clinically diagnosed dementia
  • Significant disease of the central nervous system
  • Severely depressed (CES-D score > 16), significantly symptomatic psychiatric disorder
  • Advanced cardiovascular disease that would make walking difficult, including history of congestive heart failure
  • Unstable insulin-dependent diabetes mellitus, received diagnosis Type 1 Diabetes, started insulin within past 3 months, hospitalized for hypoglycemia within past 6 months.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04863378). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search